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The optimal management of multi-vessel coronary artery disease (CAD) is a complex medical decision with significant 
prognostic implications. Despite the advent of clinical 
and angiographic scores to aid treatment delineation, 
therapy for multivessel CAD should be tailored in each 
case with regards to the patient’s clinical presentation.1 
Coronary artery bypass grafting (CABG) surgery 
and percutaneous coronary intervention (PCI) are 
potential treatment options for patients with advanced 
CAD evaluated using the SYNTAX score, as stated in 
the European Society of Cardiology and the European 
Association for Cardio-Thoracic Surgery guidelines 
on myocardial revascularisation.2 This case describes 
a patient with multivessel CAD who was treated 
successfully with a combination of drug-eluting stents 
and bioresorbable vascular scaffolds.
Case Report
A 67-year-old male was admitted to the Department 
of Cardiac, Thoracic & Vascular Sciences, Padua 
University Hospital, Padua, Italy, in 2014 with a 
non-ST-elevation myocardial infarction. He had T 
wave inversion in leads V1–4 and mildly increased 
myocardial necrosis biomarkers (peak troponin I: 
2.770 µg/L; upper reference value: 0.015 µg/L). The 
patient had previously experienced a silent myocardial 
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abstract: Optimal management of multivessel coronary artery disease can be complex. We report a 67-year-old 
male patient who was admitted to the Padua University Hospital, Padua, Italy, in 2014 with a non-ST-elevation 
myocardial infarction. Coronary angiography showed diffuse multiple sub-occlusive lesions of the proximal and 
distal left coronary vessels involving a long segment of the vessel. On intravascular ultrasonography (IVUS), the left 
main artery was moderately diseased with critically stenotic and calcified branch ostia. A successful percutaneous 
coronary intervention using the T-stenting and small protrusion technique with two drug-eluting stents (DES) was 
performed on the left main artery and its main branches. Two bioresorbable vascular scaffolds were also deployed 
in overlap at the mid to distal segments of the left anterior descending artery and overlapping a previous DES at the 
proximal segment. The full expansion and apposition of the struts and scaffolds to the vessel wall without residual 
stenosis was confirmed by IVUS.
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اىل  ادخل  �صنه   67 العمر  بالغ من  املتعددة معقده. نعر�ض حاله ملري�ض  التاجيه  القلب  املثلى الأمرا�ض �رضايني  اإن املعاجلة  امللخ�ص: 
الت�صخي�صية  الق�صطرة  اأظهرت   .ST ارتفاع  بدون  قلبي  احت�صاء  ب�صبب   2014 عام  يف  اإيطاليا،  بادوفا،  مبدينة  بادوفا،  جامعة  م�صت�صفى 
ل�رضايني القلب التاجيه ت�صيقات ان�صداديه متعددة منت�رضة يف ال�رضايني التاجيه القا�صية والدانية الي�رضى ت�صمل جزء كبري منها. وجد عن 
طريق ا�صتخدام اال�صعه املوجيه داخل االأوعية الدمويه )IVUS( اأن ال�رضيان التاجي الرئي�صي االأي�رض كان م�صابا اإ�صابة متو�صطة بت�صيق 
اإن�صدادي حاد متكل�ض. اأجري بنجاح راأب الوعاء التاجي من خالل تقنية ت�صمل اإجراء نتوء �صغري يف اجللد بدعامات T با�صتخدام دعاماتني 
اإثنني من �صقاالت االأوعية الدموية ب�صكل مرتاكب يف  اإدخال  الرئي�صية. مت  الرئي�صي االأي�رض وفروعه  )DES( على ال�رضيان  الدواء  الدخال 
الن�صف االأخري لل�رضيان االأمامي االأي�رض النازل وركب على DES �صابق يف اجلزء الداين. مت التاأكد من التو�صع ال�صامل للدعامات وال�صقاالت 
.IVUS جلدار الوعاء الدموي دون ت�صيق متبقي عن طريق
اأ�صعه موجيه؛ ت�صيقات تاجيه؛ احت�صاء قلبي؛ تقرير حاله؛  كلمات مفتاحية: دعامه تاجيه من النوع الدوائي؛ تدخالت عالجيه تاجيه عن طريق اجللد؛ 
اإيطاليا.
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diffuse calcified and atherosclerotic segments with 
multiple sub-occlusive proximal and distal left CAD 
lesions involving the left main trunk with haziness 
at the proximal segment of the left circumflex (LCx) 
artery. Despite evaluation from several planes, the 
angiographic assessment was inconclusive and the 
stenosis of the proximal LCx artery remained unclear 
[Figure 1]. Intravascular ultrasonography (IVUS) using 
a catheter (Eagle Eye® Catheter, Volcano Corp., San 
Diego, California, USA) revealed that the left main 
trunk was moderately diseased [Figure 2] with 
critically calcified branch ostia. The angiographic 
SYNTAX score of the patient was calculated to be 40. 
Due to the anatomical complexity of the distal 
coronary arteries, the patient was referred for a 
multiple lesion PCI. A decision was made to combine 
rigid cage stents for the proximal wide lumen segments 
and bioresorbable vascular scaffolds for the diffuse 
infarction without significant clinical sequelae as 
confirmed by echocardiographic follow-up which 
showed normal dimensions with preserved systolic 
left ventricular function (left ventricular end-diastolic 
volume index: 65 mL/m2; ejection fraction: 58%) 
without wall motion abnormalities. At this time, the 
patient was asymptomatic without residual ischaemia. 
This was confirmed by a negative exercise stress test at 
150 W. The patient was a smoker and had several other 
cardiovascular risk factors, including hypertension, 
dyslipidaemia and type 2 diabetes mellitus. 
At presentation, the patient was immediately 
administered 250 mg of intravenous aspirin and 
180 mg of oral ticagrelor. As he had a high Global 
Registry of Acute Coronary Events risk score (145), an 
emergency coronary angiogram was carried out using 
the right radial artery. This revealed non-significant 
stenosis of the dominant right coronary artery and 
 
Figure 1A–C: Coronary angiography of a 67-year-old male patient from the (A) cranial right anterior oblique (RAO), 
(B) caudal RAO and (C) caudal left anterior oblique views showing multiple diffuse critical lesions of the proximal and 
distal segments of the left coronary arteries involving the left main trunk with a hazy proximal left circumflex artery 
(LCx) lesion. Despite evaluation from several planes, the stenosis of the proximal LCx artery remained unclear.
 
Figure 2A–C: Intravascular ultrasonography (IVUS) of a 67-year-old male patient showing (A) moderate left main 
trunk disease, (B) multiple significant stenoses of the left anterior descending artery and (C) stenosis of the proximal left 
circumflex artery with eccentric superficial and deep dense calcific plaque (arrow).
MLA = minimal lumen area.
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eluting stent (Xience Prime®) at the level of the left main 
trunk-proximal segment of the LAD artery. This was 
followed by another 3.5 x 12.0 mm everolimus-eluting 
stent (Xience Prime®) at the left main trunk-proximal 
segment of the LCx artery. Kissing balloon postdilation 
was then performed in the bifurcation of the left main, 
LAD and LCx coronary arteries. Finally, after the 
mid-distal LAD artery lesions were prepared using an 
incremental semi-compliant balloon, excluding the 
recurrent apical segment, two bioresorbable vascular 
scaffolds (Absorb Bioresorbable Vascular Scaffold, 
Abbott Vascular) of 3.0 x 28 mm and 2.5 x 28 mm, 
respectively, were positioned proximally to the distal 
segments, with minimal overlap (marker-to-marker 
implantation) at the mid- to mid-distal segment of the 
LAD artery and overlapping the metallic cage stent at 
the proximal segment of the LAD artery. 
Following the intervention, a coronary angiogram 
showed that all vessel side branches were maintained 
without evidence of any complications. Full expansion 
and complete apposition of the metallic struts to the 
vessel wall at the proximal segments was confirmed 
via IVUS [Figure 3]. Similarly, the uniform and full 
expansion of the bioresorbable scaffolds apposed 
to the intimo-medial membrane at the mid-distal 
LAD artery was observed without residual stenosis 
via angiography and IVUS [Figure 4]. The patient 
remained asymptomatic without further cardiac 
events and was discharged one week after admission 
on a 12-month course of dual antiplatelet therapy. 
At a six month clinical follow-up, the patient was 
symptom-free.
Discussion
Consideration of the coronary anatomy, disease 
complexity, the presence of left ventricular dys-
function and SYNTAX risk score, along with any 
atherosclerotic lesions which involved the long mid-
distal segments of the left anterior descending (LAD) 
artery. Due to severe calcifications on the mid-distal 
LCx artery, percutaneous transluminal coronary 
angioplasty was performed. Instead of a bioresorbable 
vascular scaffold, a single 2.5 x 23.0 mm everolimus-
eluting stent (Xience Prime®, Abbott Vascular, Santa 
Clara, California, USA) was implanted at the mid-
distal LCx artery in order to avoid suboptimal scaffold 
expansion/apposition. After preparation of the lesions 
with semi-compliant balloons, a successful two-stent 
approach using the T-stenting and small protrusion 
technique was performed at the left main trunk and 
its main branches using a 3.5 x 33.0 mm everolimus-
 
Figure 4A–C: A: Post-interventional coronary angio-
graphy of a 67-year-old male patient following the 
implantation of two bioresorbable vascular scaffolds at 
the mid-distal portion of the left anterior descending 
artery and in overlap with a drug-eluting stent at 
the proximal portion. B and C: Cross-sectional 
intravascular ultrasonography images corresponding 
to sections of the coronary angiogram (yellow lines) 
showing the uniform and full expansion of the struts 
and scaffolds apposed to the intimo-medial membrane. 
All three concentric stents and scaffold layers were 
noted at overlap sites as discrete echo-bright structures.
DES = drug-eluting stent; BVS = bioresorbable vascular scaffold.
 
Figure 3A–C: Post-interventional cross-sectional intravascular ultrasonography of a 67-year-old male patient following 
the implantation of two bioresorbable vascular scaffolds and two drug-eluting stents. The stents were well-apposed and 
expanded with no signs of dissection at the (A) left main trunk, (B) proximal portion of the left anterior descending artery 
and (C) proximal portion of the left circumflex artery.
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comorbidities, interventional risks, long-term 
outcomes, local expertise and the patient’s personal 
preferences, are imperative when making decisions 
regarding treatment for patients with multivessel 
CAD.1,3 For patients with SYNTAX scores over 22, 
CABG surgery is associated with better long-term 
outcomes than PCI, barring the presence of excessive 
preoperative risk factors.3 Research indicates that 
diabetic patients affected by CAD respond better 
to CABG treatment over PCI, particularly patients 
with severe and diffuse CAD.4–6 One recent trial 
involving patients with diabetes mellitus and advanced 
multivessel CAD found that CABG treatment was 
beneficial in that it significantly reduced rates of death, 
myocardial infarction and repeated revascularisation 
at a five-year follow-up, although a higher rate of 
strokes was observed.6 Based on this trial, CABG 
surgery is recommended as the preferred treatment 
for patients with multivessel CAD, as it has the most 
favourable long-term outcomes in patients with a 
high SYNTAX score but without high surgical risk.4,6 
Alternatively, patients who are at high risk for surgery, 
or who have low-severity CAD, should undergo PCI 
treatment.5 The patient in the current case presented 
with a high-risk SYNTAX score and angiographic 
evidence of multivessel CAD; treatment with PCI was 
chosen as CABG surgery was deemed unsuitable due 
to the anatomical complexity of the distal coronary 
arteries. As distal coronary stenoses may affect 
adenosine-mediated vasodilation leading to a false-
negative result, the fractional flow reserve technique 
was not used to evaluate the PCI target.
The present case illustrates the importance of 
tomographic techniques—such as IVUS imaging—
over coronary angiography in the diagnosis and 
management of complex multivessel CAD. In the 
current case, IVUS showed moderate left main trunk 
disease and critically calcified ostial lesions of the 
LAD and LCx arteries. However, in comparison with 
conventional intravascular imaging modalities such 
as IVUS, optical coherence tomography has a higher 
resolution (range: 10–15 μm), allowing for the more 
accurate detection and quantification of scaffold 
malapposition, underexpansion, tissue prolapse or 
stent edge dissection. Recently, research has shown 
that optical coherence tomography can be used to 
identify adverse cardiac features requiring immediate 
intervention in a large proportion of patients, resulting 
in improved clinical outcomes.7 Unfortunately, this 
alternative imaging technology was not available 
at the Padua University Hospital at the time of 
the intervention.
The implantation of multiple metallic stents 
covering long coronary segments can substantially 
affect vasomotion and may cause vascular 
inflammation, restenosis, thrombosis and neoathero-
sclerosis.8–10 Permanent metallic platform stents 
also indefinitely impair the physiological vasomotor 
functioning of the vessel; hence the coronary geometry 
and systo-diastolic movement of coronary arteries 
treated with metallic stents remain similar up to a year 
after implantation.9,10 Bioresorbable vascular scaffolds 
have the potential to overcome these limitations as 
they provide a temporary scaffolding which disappears 
after 2–3 years, liberating the treated vessel, and can 
help to restore the vessel’s original shape, preserving 
laminar blood flow, reducing the plaque-to-media 
ratio and restoring the vasomotion, pulsatility, cyclical 
strain, adaptive shear stress and mechanotrans- 
duction of the vessel.8,9,11 Following PCI, the absence 
of any residual foreign material and restoration of 
functional endothelial coverage can also reduce 
the risk of stent thrombosis, myocardial infarction, 
sudden death and the need for long-term dual 
antiplatelet therapy; in addition, PCI does not exclude 
the possibility of future graft anastomosis in case the 
need for future bypass surgery arises.8,9 However, 
there are as yet no data with regards to the feasibility 
of performing CABG surgery at coronary sites 
which have previously undergone implantation of a 
bioresorbable vascular scaffold. 
After implantation, the bioresorbable vascular 
scaffold maintains sufficient radial strength to prevent 
vessel recoil and releases the drug to inhibit the 
proliferation of neointima. However, the scaffold’s 
mass and radial strength gradually decrease over time 
and it vanishes completely after 2–3 years, leaving the 
vessel covered with a healthy endothelium and with 
normal vasomotor function.8 Bioresorbable vascular 
scaffolds should be predominantly used in young 
patients for whom multiple long stents are required, 
particularly those with long lesions or diffuse disease; 
patients with lesions located in the mid-distal portion 
of the coronary arteries will also benefit because 
the use of bioresorbable vascular scaffolds does not 
preclude potential bypass grafting in the future.8 For 
severely calcified vessels, preparation of the lesion 
with optimal pre-dilatation or the use of additional 
devices and procedures such as cutting and scoring 
balloons or rotational atherectomy is crucial for the 
successful implantation of the scaffold. Even severely 
calcified vessels will benefit from the disappearance 
of the scaffold, as this reduces the risk of late stent 
thrombosis and can lead to late lumen gain.8
No guidelines currently exist on the simultaneous 
use of drug-eluting stents and bioresorbable vascular 
scaffolds to manage diffuse critical atherosclerotic 
multivessel CAD. Gil et al. recently reported that the 
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concurrent use of these devices might be safe and 
effective, with no mortality or incidents of myocardial 
infarction or stent thrombosis observed at a 12 month 
follow-up and very few cases of clinically-driven 
target lesion revascularisation.12 The rationale for 
using both devices in the current case was to treat 
the diffuse disease percutaneously while avoiding 
the use of long metallic stented segments. Due to 
the diffuse disease at the mid-distal LAD artery, the 
patient’s anatomy was not deemed suitable for CABG 
surgery. On the other hand, the presence of lesions at 
the left main trunk and proximal LAD artery supports 
coronary revascularisation over medical treatment, 
especially for acute coronary syndromes such as non-
ST-elevation myocardial infarctions.2,13 As a result, 
PCI was performed; however, as multiple lesions and 
segments required treatment, coronary bioresorbable 
vascular scaffolds were used to avoid mid-to-long-
term drug-eluting stent-related adverse events (e.g. 
stent thrombosis and restenosis).8,9 In addition, 
implanting a long metallic drug-eluting stent at the 
distal coronary bed could potentially affect coronary 
flow or the outcome of future CABG surgeries.9,10 
Nevertheless, metallic stents were also implanted at 
proximal sites due to the limitations of bioresorbable 
vascular scaffolds for large vessels, bifurcations (i.e. 
the left main trunk lesion in the current patient) and 
severely calcified lesions.9,11
Conclusion
Lesions in the left main coronary artery are rarely 
isolated and the coronary anatomy is not always 
suitable for a CABG surgical approach, regardless of 
risk scores. As with the current case, a combination 
of drug-eluting stents and bioresorbable vascular 
scaffolds can be a feasible treatment option for 
complex diffuse multivessel CAD with left main trunk 
involvement. The use of non-metallic bioresorbable 
vascular scaffolds in long diffuse lesions of the mid-
distal vessels, in combination with metallic struts in 
the proximal segment, may mitigate the adverse effects 
of metallic stents. This technique ensures adequate 
and temporary scaffolding while also promoting 
adequate healing of the vessel wall and allowing for 
the possibility of future graft anastomosis should the 
patient subsequently need CABG surgery.
